Fundraising FoxOphirex
Corte Madera, US · Delaware corporation · 2 known investors
Find your way into Ophirex
Sign up to see every warm intro you have to Ophirex
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ophirex team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Ophirex is a biotech company developing varespladib, an investigational oral capsule intended to treat snakebite envenomation by inactivating a key venom toxin found in most snake species. The drug is designed as a portable, field-administered rescue treatment to bridge the gap before hospital antivenom.
Founders & leadership
JH.jpg)
Jerry HarrisonCo-founder; Director
MR
Matthew R. LewinFounder and Board MemberMatthew Lewin is an emergency physician and neuroscientist with expertise in expedition medicine; he founded the Center for Exploration and Travel Health and Snakebite Project at the California Academy of Sciences and is co-founder of Ophirex, a biotech company developing oral treatments for snakebite envenomation.
JG
Jeremy GowlerChief Executive Officer & Board DirectorJeremy Gowler is an executive at Ophirex, a biotech company developing varespladib, an oral treatment for snakebite envenomation. He has held C-suite and board positions in healthcare, with experience in general management, marketing, sales, business development, and medical affairs across product lifecycle stages, ranging from startups to established corporations.
SC
Sara CarterExecutive
TP
Timothy Platts-MillsExecutive
D
DotsonFinance leader (Controller/Finance)
HP
Howard PienNamed on SEC filing
NJ
Nancy J. KochNamed on SEC filing
Investors · 2
Global Health Investment FundreportedNew York
How we know: a partner's Signal profile · Not right? Tell us
Funding
SEC filings, press & company announcements$16.5M disclosed across 1 of 3 rounds · 2019–2023
- Undisclosed amountSeries BJan 2023Source ↗
▶$16.5MraisedMar 2022 · 18 investors · OtherRule 506(b)
▶$16.5MraisedMar 2022 · 18 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Jeremiah HarrisonDirector
- Derrick RossiDirector
- Curt LaBelleDirector
- Hans BishopDirector
- Timothy GarnettDirector
- Nancy J. KochExecutive Officer, Director
- Matthew R. LewinDirector
- Offering amount
- $35M
- Amount sold
- $16.5M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MofferedMar 2019 · OtherRule 506(b)
▶$5MofferedMar 2019 · Other
Rule 506(b)Officers, directors & promoters on the filing
- Jerry HarrisonDirector, Promoter
- Matthew LewinExecutive Officer, Director, Promoter
- Howard PienDirector, Promoter
- Nancy J. KochExecutive Officer, Director, Promoter
- Offering amount
- $5M
- Minimum investment
- $5K
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
MedscapeMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.
GaviGavi is a public-private partnership that funds vaccination programs in developing countries through contributions from governments, foundations, corporations, and private donors. The organization mobilizes resources to provide vaccine access and shape vaccine markets in supported nations.
Companies working in the same space as Ophirex.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Department of DefenseDefense Health Program | Phase II | 2023 | $1.3M |
| Department of DefenseDefense Health Program | Phase II | 2021 | $1.5M |
| Department of DefenseDefense Health Program | Phase I | 2018 | $148.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Ophirex do?
- Ophirex is a biotech company developing varespladib, an investigational oral capsule intended to treat snakebite envenomation by inactivating a key venom toxin found in most snake species. The drug is designed as a portable, field-administered rescue treatment to bridge the gap before hospital antivenom.
- Who founded Ophirex?
- Ophirex was founded by Jerry Harrison, Matthew R. Lewin.
- Who are Ophirex's investors?
- Ophirex's investors include Global Health Investment Fund, Tullis Health Investors.
- How much funding has Ophirex raised?
- Ophirex has disclosed $16.5M raised across 1 of its 3 known rounds.
- Where is Ophirex headquartered?
- Ophirex is headquartered in Corte Madera, US.